KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at HC Wainwright from $27.00 to $37.00. They now have a "buy" rating on the stock.
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results [Yahoo! Finance]
KalVista Pharmaceuticals Provides Update on Strong EKTERLY® Launch with Preliminary Fourth Quarter and Full Year 2025 Revenue Results
KalVista Pharmaceuticals (NASDAQ:KALV) had its price target raised by analysts at Needham & Company LLC from $28.00 to $32.00. They now have a "buy" rating on the stock.
KalVista Pharmaceuticals Announces Approval of EKTERLY® (sebetralstat) in Japan, First and Only Oral On-demand Treatment for Hereditary Angioedema